北京商报讯(记者王寅浩)12月18日,中国生物制药发布公告称,其自主研发的1类创新药贝莫苏拜单抗注射液联合或不联合盐酸安罗替尼胶囊在非小细胞肺癌(NSCLC)放化疗后巩固治疗的III期研究取得阳性结果。 该研究的期中分析显示,贝莫苏拜单抗的联合治疗显著延长了患者的无进展生存期(PFS),并降低了疾病进展或死亡风险。独立数据监查委员会已判定主要研究终点达到预设的优效界值。集团已与中国...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.